🧬Prospective Exclusive Patent License for Cancer Treatment Innovations
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an NCI Exclusive Patent License to practice the inventions embodied in the patents listed in the Supplementary Information section of this notice to Lysin Therapeutics, Inc. (Lysin), a company located in Silver Spring, MD.
Learn More🏥Change in Meeting Time for Innovations in Nanosystems Study Section
The Department of Health and Human Services announced an amended notice of a meeting for the Innovations in Nanosystems and Nanotechnology Study Section. The meeting is scheduled for October 8-9, 2025, with a revised start time of 9
Learn More🚬Proposed CDC Data Collection on Smokeless Tobacco Ingredients
The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a continuing information collection project titled Annual Submission of the Ingredients Added to, and the Quantity of Nicotine Contained in, Smokeless Tobacco Manufactured, Imported, or Packaged in the U.S. This activity is designed to allow CDC to collect a list of ingredients added to tobacco in the manufacture of smokeless tobacco products and a specification of the quantity of nicotine contained in each product.
Learn More💰NIH Meetings on Grant Applications
The Department of Health and Human Services announces closed meetings held by the National Institutes of Health to review grant applications across various scientific disciplines. These meetings aim to evaluate applications that may involve confidential and proprietary information, highlighting the ongoing commitment to funding vital research initiatives within the health sector.
Learn More💉National Vaccine Injury Compensation Program
HRSA is publishing this notice of petitions received under the National Vaccine Injury Compensation Program (the Program), as required by the Public Health Service (PHS) Act, as amended. While the Secretary of HHS is named as the respondent in all proceedings brought by the filing of petitions for compensation under the Program, the United States Court of Federal Claims is charged by statute with responsibility for considering and acting upon the petitions.
Learn More📜Final Rule Correction on Standards of Conduct by HHS
OS is correcting a final rule that was published in the Federal Register on August 22, 2025, with an effective date of October 21, 2025. The Standards of Conduct Final Rule revises, republishes, and renumbers, as needed, the sections of part 73 that have not been superseded and continue to be important to the efficient functioning of the Department to ensure they are consistent with current law and Department policy or procedures. It includes required provisions related to counter-trafficking in persons and removes all superseded and obsolete provisions, including parts 73a and 73b, in their entirety.
Learn More💰NIH Closed Meetings on Grant Evaluations
The Department of Health and Human Services announces closed meetings for the Center for Scientific Review, focusing on the evaluation of various grant applications in health and research sectors. These meetings, scheduled virtually, outline significant funding opportunities that aim to advance scientific inquiry and innovation. Additionally, the sessions will maintain the confidentiality of sensitive information as mandated by federal regulations.
Learn More🏥Closed Meeting Notice for National Institute of Allergy and Infectious Diseases
The Department of Health and Human Services announces a closed meeting of the Division of Intramural Research Board of Scientific Counselors, NIAID. The meeting aims to review individual programs and performance, ensuring privacy for involved personnel. Key details include the meeting's date, time, and location, as well as contact information for inquiries.
Learn More💊FDA Corrects Drug Approval Notice for Bausch & Lomb and Others
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on March 14, 2025 (90 FR 49), appearing on page 12163 in FR Doc. 2025-04106. The document announced the withdrawal of approval of eight abbreviated new drug applications (ANDAs) from multiple applicants, withdrawn as of April 14, 2025. The document indicated that FDA was withdrawing approval of the ANDA 075819 for amantadine hydrochloride syrup, 50 milligrams/5 milliliters, held by CMP Pharma, Inc., 8026 East Marlboro Rd., P.O. Box 147, Farmville, NC 27828. Before FDA withdrew the approval of this ANDA, CMP Pharma, Inc., 8026 East Marlboro Rd., P.O. Box 147, Farmville, NC 27828, informed FDA that they did not want the approval of the ANDA withdrawn. Because CMP Pharma, Inc., timely requested that approval of the ANDA not be withdrawn, the approval is still in effect. This notice corrects this error.
Learn More💰NIH Center for Scientific Review Announces Grant Evaluation Meetings
The Department of Health and Human Services announces closed meetings for the Center for Scientific Review, focusing on the evaluation of grant applications in various health sectors. The meetings address crucial topics in clinical data management, oncology, and biotechnology, impacting the funding landscape for businesses involved in health-related research and development efforts.
Learn More